Abstract Purpose: To investigate the incidence and extent of stent frame movement after endovascular aneurysm sealing (EVAS) in the abdominal aorta and its relationships to aneurysm growth and the instructions for use (IFU) of the Nellix endograft. Methods: A retrospective single-center study was conducted to review the clinical data and computed tomography (CT) images of 75 patients (mean age 76±7.6 years; 57 men) who underwent infrarenal EVAS and had a minimum 1-year followup. The first postoperative CT scan at 1 month and the subsequent scans were used to measure the distances between the proximal end of the stent frames and a reference visceral vessel using a previously validated technique. Device migration was based on the Society of Vascular Surgery definition of >10-mm downward movement of either Nellix stent frame in the proximal landing zone; a more conservative proximal displacement measure (downward movement ⩾4 mm) was also recorded. Patients were categorized according to adherence to the old (2013) or new (2016) Nellix IFU. Aneurysm diameter was measured for each scan; a change ⩾5 mm was deemed indicative of aneurysm growth. Results: Over a median follow-up of 24 months (range 12-48), proximal displacement ⩾4 mm occurred in 42 (56%) patients and migration >10 mm in 16 (21%), with similar incidences in the right and left stent frames. Proximal displacement was significantly more frequent among patients whose anatomy did not conform to any IFU (p=0.025). Presence of aneurysm growth ⩾5 mm was observed in 14 (19%) patients and was significantly associated with proximal displacement ⩾4 mm (p=0.03). Conclusion: Infrarenal EVAS may be complicated by proximal displacement and migration, particularly when performed outside the IFU. The definition of migration used for endovascular aneurysm repair may be inappropriate for EVAS; a new consensus on definition and measurement technique is necessary.
Introduction
Endovascular aneurysm sealing (EVAS) performed with the Nellix endoprosthesis (Endologix Inc, Irvine, CA, USA), which received Conformité Européenne marking in April 2013, is a relatively new treatment strategy for the repair of abdominal aortic aneurysm (AAA). [1] [2] [3] Only midterm data are available at present, and multiple studies [4] [5] [6] [7] [8] have reported type I and type II endoleaks in addition to migration. [6] [7] [8] [9] [10] Early outcomes dictated a change in the instructions for use (IFU) in October 2016, 11 with modifications aimed at reducing the occurrence of mig ration. The aim of this study was to establish the incidence and consequences of stent movement after infrarenal EVAS and its relationship to aneurysm growth and adherence to the IFU.
Materials and Methods

Study Design and Patient Sample
This was a retrospective, singlecenter, observational study of patients treated with infrarenal EVAS between December 2013 and January 2018. The operative technique used has been described elsewhere. 12 Informed consent was obtained, which included an understanding that procedural outcomes would be evaluated and reported accordingly. The followup protocol included abdominal radiography on the first day, duplex ultrasound and arterialphase computed tomography (CT) at 1 month, and yearly abdominal radiographs, duplex scans, and arterialphase CT scans. Patients with significant renal impairment who had normal 1month CT scans and favorable anatomical features as judged by an experienced operator (R.G.M.) had only radiography and ultrasound scans in followup. CT data were reconstructed using the thinnest available slice (⩽2 mm) before review. This project fell within a program of studies evaluating EVAS at our institution; therefore, formal ethics approval was not required as the study was registered as a service review.
Eligibility for the study was based on availability of a base line postoperative CT scan at 1 month (maximum 100 days after device implantation) and at least 1 additional CT scan (minimum of 12 months from the initial implantation) in the Digital Imaging and Communication in Medicine format.
During the observation period, 112 consecutive patients underwent EVAS. Excluded were 19 patients in whom CT images were not available, 11 patients undergoing EVAS extending into the suprarenal segment with chimneys, 6 patients undergoing EVAS as a secondary intervention after previous aortic aneurysm surgery, and 1 patient treated for ruptured aneurysms. The remaining 75 patients (mean age 76±7.6 years; 57 men) were included in the study. Pre operative anatomical data are displayed in Table 1 . EVAS was performed using paired stents in all but 3 patients, who received an aortouniiliac device.
Measurements 10
A builtin vessel analysis module (Carestream version 11.4.1.1011; Carestream Health Inc, Rochester, NY, USA) on the Picture Archiving and Communications System (PACS) was used to measure stent frame movement. Each scan was loaded onto a PACS workstation to generate a semiautomated central lumen line (CLL) through each stent frame using the "Aorta Protocol" tool, which automatically switched between stent frames and provided a more unified generation of the stent frame CLL. The CLL of each stent frame was checked by scrolling through all the anatomical planes, ensuring that it was indeed traveling through the center of the lumen.
A 2dimensional oblique axial view perpendicular to the CLL was used to determine the position of the stent frame against the specified reference point. This reference was the point most inferior of the superior mesenteric artery (SMA) where a clear separation of the SMA from the aortic wall was visible on the first oblique axial CLL reformatted image. The distance between this point and the first oblique axial CLL reformat that contained at least 2 stent struts was measured, reducing the probability of mistaking calcification for the actual stent frame. Each CLL measurement was compared with the same measurement on the 1year CT scan and, if available, subsequent scans. Measurement differences between the CT scan at 1 month and subsequent scans at the same anatomical location were used to determine whether device movement had occurred. Caudal movement was indi cated by a positive value and cranial with a negative value. The bias (difference between true movement and the CT assessment) and intra/interobserver variability of this method have been previously assessed for stentgraft migration. 14 
Outcome Measures and Definitions
The primary outcome measure was the incidence of stent movement as well as its relationship with aneurysm growth and adherence to the IFU. The reporting standards of the Society for Vascular Surgery (SVS) define device migration as movement >10 mm relative to anatomical landmarks or any migration leading to symptoms or requiring therapy. 13 However, in a recent study, England et al 14 specifically defined stent migration for the EVAS device as ⩾4 mm rela tive to a vascular landmark, a cutoff that has also been used to define migration in fenestrated stentgrafts. 15 This study therefore reported EVAS stent frame proximal displacement (⩾4 mm) and migration (>10 mm) as defined by the SVS.
Aneurysm diameter was measured as the maximum crosssectional diameter on reconstructed slices perpendic ular to the main aortic axis, measuring from adventitia to adventitia. Aneurysm growth was defined as a change ⩾5 mm between the 1month CT and subsequent scans.
Since the Nellix IFU changed in October 2016, 11 when more restrictive anatomical criteria were introduced, this study assessed if the aortic anatomy of the patients was within or outside the old IFU (IFU2013) 16 or the new, refined IFU (IFU2016).
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Data Analysis
Continuous variables were assessed for normality using the KolmogorovSmirnov test and are presented as mean ± standard deviation or median and absolute range according to the underlying distributions. Paired comparisons were performed with a t test or MannWhitney U test as appropri ate. KaplanMeier survival curves were generated to esti mate freedom from proximal displacement or migration; the logrank test was used to compare estimates between IFU groups. The Fisher exact test was used to identify any asso ciation of aneurysm growth with proximal displacement or migration. The threshold of statistical significance was p<0.05. SPSS software (version 22.0; IBM Corporation, Armonk, NY, USA) was employed to analyze the data.
Results
There were no perioperative deaths, but 19 (25%) patients experienced a complication within 30 days; 7 (9%) required a secondary intervention (Table 2 ). There was 1 operative type Ia endoleak, which resolved at 48 hours. Eight patients died during followup; none was aneurysm related.
Over a median followup of 24 months (range 12-48), 42 (56%) patients displayed proximal displacement ⩾4 mm in one or both stent frames: 25 (33%) of the 75 patients with 1year followup, 12 (28%) of 43 with 2year followup, and 5 (33%) of 15 with 3year followup. Sixteen (21%) patients had migration >10 mm: 5 (7%) of 75 at 1 year, 6 (14%) of 43 at 2 years, 4 (27%) of 15 at 3 years, and 1 (50%) of 2 at 4 years. There were no differences in the inci dences of proximal displacement/migration between the left and right stent frames irrespective of the definition (Table  3 ). Figure 1 shows the evolution of proximal displacement and migration in time.
Three patients, all with evidence of proximal displace ment or migration, demonstrated a type Ia endoleak during followup. A total of 12 (16%) patients underwent late rein tervention; 8 had ⩾4mm proximal displacement and 4 had migration more than 10 mm. The details of the reinterven tions and their relationship with proximal displacement or migration are summarized in Table 4 . Figure 2 shows free dom from proximal displacement and migration for the left and right stent frames and the whole cohort. In the study cohort, the anatomical features of 20 (27%) patients were within both the IFU2013 and IFU2016. Fiftyfive (73%) patients were within IFU2013; of these, 35 (47%) were outside the new IFU2016. Twenty (27%) patients were outside both IFU2013 and IFU2016. As summarized in Table 5 , proximal displacement/migration was affected by compliance with the IFU. The highest inci dence of proximal displacement (70%) was observed when the device was outside both IFUs; this rate reduced to 30% when the anatomy was within the new IFU2016. Figure 3 shows freedom from proximal displacement and migration of each IFU group. Proximal displacement was signifi cantly more frequent among patients whose anatomy did not conform to any IFU (p=0.025).
During followup, 14 (19%) patients displayed aneurysm growth ⩾5 mm (median 5.5; range 5-15), which was sig nificantly associated with proximal displacement (p=0.03). Proximal displacement preceded aneurysm growth in 6 patients, followed aneurysm growth in 3, and appeared with aneurysm growth on the same scan in 3 patients. Aneurysm growth was detected but there was no proximal displace ment in the other 2 patients.
Discussion
This study confirms that proximal stent frame displacement occurs in a significant proportion of patients who undergo EVAS and is associated with anatomy outside the current IFU. Movement can be progressive, can affect one or both stent frames, and is associated with aneurysm growth, a finding that has not been described before.
In a previous study with a much smaller cohort and shorter followup, 10 our group reported the occurrence of postEVAS stent frame proximal displacement, defined and measured as in the present study. Migration and other types of stent frame displacement have also been described by other authors, [6] [7] [8] [17] [18] [19] although the definition and mea surement techniques have not been consistent in the litera ture. In contrast, van den Ham et al 20 did not observe migration in patient cohorts with high adherence to the IFU at 1 year.
The current study used 2 definitions for stent frame dis placement. The >10mm criterion long employed for EVAR 13 may be outdated, partly because modern cross sectional imaging allows the detection of much smaller device movements and more specifically because of the inherent differences between EVAR and EVAS, which seals without radial force or active fixation. As aortic necks are rarely perfectly cylindrical, even small postEVAS stent frame movements may result in loss of contact between the endobags and the aorta (or between the 2 endobags), with consequent loss of seal and repressurization of the aneu rysm. For these reasons, this study also reported proximal displacement according to a more conservative (⩾4 mm) definition that has previously been used for fenestrated EVAR 15 and EVAS. 21 Interestingly, IFU2016-compliant patients displayed approximately half the incidence of proximal displacement as the rest of the patients, regardless of definition (⩾4 or >10 mm).
While proximal stent displacement may be of particu lar relevance in short aortic necks, its potential clinical impact would also depend on the length of endobag/aorta apposition at the landing zones (the "seal"). In our experi ence, however, it is not always possible to measure the length of seal on CT scans, particularly in narrow necks, where the contour of the endobags is difficult to define. Thus this variable was not included in the study because there was insufficient confidence in the ability to measure it reliably.
The incidence of proximal displacement demonstrated here should be interpreted in context by comparing it to that of standard EVAR when the latter is measured with similar criteria. A recent systematic review 22 demonstrated an 8.6% incidence of postEVAR proximal displacement (⩾5 mm) at 1 to 3 years, which was associated with poor anatomy and, unlike our study, with type Ia endoleaks.
A significant incidence of aneurysm growth was also observed in our series but only 3 late endoleaks. It is gener ally thought that aneurysm growth rarely occurs in the absence of aneurysm perfusion and pressurization. It is also accepted that aneurysm pressurization postEVAS can occur in the absence of a visible endoleak. 23 Our findings thus suggest that even small degrees of proximal displace ment may be clinically significant. It is possible that small movements may allow blood to seep between the endobags and the aorta or between the endobags, effectively creating a wedgelike communication between the proximal circula tion and the aneurysm. Even after thrombosis of such a communication, aneurysm growth may occur, as thrombus is capable of transmitting pressure. 24 EVAS may thus behave differently from EVAR during followup.
Our group recently highlighted the potential effect of certain forces (such as gravity and vibration) on implanted Nellix prostheses. 25 These forces would not be expected to have the same effect after EVAR due to the difference in mass between traditional endografts and the Nellix prosthe sis. While it is still unclear whether such effects have sig nificant clinical consequences, their observation underlines that posttreatment evolution of aneurysms treated by EVAS may be different from that of aneurysms treated by EVAR.
While it is logical to assume that aneurysm growth follows proximal displacement/migration, it is also theoretically pos sible that proximal displacement could be secondary to aneu rysm growth as such growth would create additional space into which the stent/endobag complex could move. The 3 cases in which aneurysm growth preceded proximal displace ment would seem to support this theory. Unfortunately, our study cannot establish whether aneurysm growth was a cause or a consequence of proximal displacement. Further research is necessary to clarify this relationship.
Our findings confirm that there is a reduction in proxi mal displacement incidence when complying with the recently refined IFU2016, which was introduced after a higher than expected incidence of migration was observed in American premarketing studies. 26 However, the proxi mal displacement rate in this group was still 30% despite adherence to the new IFU. van Noort et al 27 recently reported a 28% rate of events (migration >5 mm, any endoleak, and/or aneurysm growth >5 mm) in their 46patient subgroup complying with the IFU2016. These results should encourage clinicians to pursue close surveil lance even in patients treated within the IFU for early detec tion of proximal displacement and AAA growth.
Limitations
This study has obvious limitations, as it was retrospective, limited to a single center, and had a relatively small popula tion. Its strengths, however, include the prospective nature of clinical data collection, ensuring comprehensive capture of clinical adverse events; the low rate of loss to followup for a retrospective study; and the previously validated CT measurement techniques. It should encourage further research on postEVAS surveillance in order to fully under stand the mechanisms that lead to treatment failure.
Conclusion
Infrarenal EVAS is prone to proximal displacement, partic ularly when performed outside the IFU. This proximal dis placement may cause aneurysm growth in the absence of endoleaks. The definition of migration used for EVAR may be inappropriate for EVAS; a new consensus on definition and measurement technique is necessary. Clinicians should continue close surveillance after EVAS, particularly in patients treated outside the IFU.
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